Acrivon Therapeutics announced preclinical data showing potent synergy between its lead drugs ACR-368 and ACR-2316 with immune checkpoint inhibitors and antibody-drug conjugates (ADCs). ACR-368, in Phase 2b trials, and ACR-2316, in Phase 1/2 trials, demonstrated enhanced anti-tumor effects when combined with anti-PD-L1 therapies and Topoisomerase 1 inhibitors. These findings highlight promising opportunities for frontline cancer treatments and will be presented at the AACR 2026 Annual Meeting. The data support further clinical development of these combinations to improve cancer patient outcomes.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
SpaceX shares fell below their IPO price of $135 for the first time, dropping to $132.28 before closing slightly above at $135.27. The stock is down about 16% from its June 12 closing price and 36% from its peak on June 16. The decline reflects inves...
Latham Group is rated a Buy as it implements a new CEO-led strategy focusing on expanding its core market, increasing presence in the southern U.S., adopting automatic pool covers, and pursuing mergers and acquisitions. Despite challenges in the depr...
NYDIG projects Bitcoin might fall to $38,000-$39,000 by October 2026 if the current 2025-26 market decline matches the depth of the 2022 bear market. Bitcoin is currently trading near $64,500, down about 30% this year and roughly 50% below its Octobe...
PepsiCo is rated a strong buy due to its attractive combination of dividend yield, earnings growth, and undervaluation. The company is projected to achieve a forward compound annual growth rate (CAGR) between 13.7% and 18.2%, supported by dividend in...
